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INTRODUCTION
High dose chemotherapy and autologous SCT (HDC auto-SCT) is well-accepted therapy for patients with aggressive non-Hodgkin's lymphoma (NHL). HDC auto-SCT has shown superior EFS and OS in patients with relapsed or refractory disease when compared with salvage chemotherapy alone. 1, 2 Over the past few years, there has been increasing use of 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) scanning in HDC auto-SCT setting. Patients with FDG-PET positive disease after salvage chemotherapy/before HDC auto-SCT are reported to have inferior outcome. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Currently, there is no comprehensive predictive model integrating FDG-PET with other clinical risk factors in this group. We are reporting our experience of pre-transplant FDG-PET results along with other prognostic factors and constructed a predictive model and its impact on outcome.
MATERIALS AND METHODS

Study design
This is a combined report of Institutional Research Advisory Council approved prospective trial and prospective data collection study. All patients and/or their guardians provided informed consent for all treatments, procedures and HDC auto-SCT as per institutional requirements.
This study evaluates the impact of post-salvage chemotherapy/pre-HDC auto-SCT FDG-PET among other prognostic/predictive factors on post-HDC auto-SCT persistent disease, progression, relapse or death in patients who underwent HDC auto-SCT. We also constructed a predictive model based on pre-transplant FDG-PET results and other prognostic factors for post-HDC auto-SCT residual/progressive disease (PD), relapse and death due to disease in these patients.
than or equal to one third of the maximum thoracic wall diameter or any mass X10 cm. International Working Group 16 response criteria were used for computerized tomography (CT) scan: complete response (CR), disappearance of all lymphoma-related abnormalities; partial response, 450% reduction; no response or stable disease as less than partial response; PD as appearance of any new lesion or 425% increase in the presence of previous lesion or appearance of disease-related symptoms. Refractory disease was defined as partial response, no response/stable disease or PD after planned multiagent chemotherapy with or without radiation therapy (XRT) or relapsing within 3 months of finishing the planned treatment after achieving a CR or CR unconfirmed. For CT scan and FDG-PET, 'positive study' was defined as study showing evidence of disease, 'negative study' as study showing no evidence of disease.
FDG-PET imaging
FDG-PET data of the whole body were obtained on PET-CT Discovery LS system (8 slice CT) by GE (10 patients before October 2005 were scanned on ECAT EXACT scanner, Siemens-CTI, Knoxville, TN, USA). Patients received a dose of 370-444 MBq FDG intravenously and scanned from mid-thigh to the crown upwards starting 90 min after injection. The measured axial field of view extended over 45 cm (3 bed positions). Fortyseven overlapping slices per bed position were acquired. Corrections for attenuation were based on measured transmission scans. Positive FDG-PET was defined as any focal or diffuse area of increased activity in a location incompatible with normal anatomy/physiology and suspect for residual disease on visual assessment. Mediastinal blood pool structure activity was used as a reference for normal uptake for residual masses 42 cm. 'Positive' results were semi-quantitatively investigated using the standardized uptake value.
Statistical analysis
Statistical analysis aims to estimate the hazard rate associated with a group of 19 predictive factors as shown in Table 3 . The study included two predictive models; the first, modeled the hazard associated with the predictive risk factor of disease-specific events after HDC auto-SCT (persistent disease, disease progression or recurrence) and the second, modeled the associated risk of disease-specific death (dying of disease) after HDC auto-SCT. Treatment-related mortality and death in remission were considered as competing events.
Competing risk analysis was performed. Cumulative incidence function was used in estimating the probability of failure. The hazard associated with the proposed predictive risk factors was modeled using the subdistribution hazard model proposed by Fine and Gray. 17 The two proposed models studied the same group of predictive risk factors.
The time frame used in modeling the disease-specific event or death was defined as time since transplant up to the occurrence of event or death respectively or last follow-up.
Univariate analysis using the competing risk regression model was performed for all the proposed risk factors. Covariates that achieved a significance level of o0.2 were taken to the multivariate model. The multivariate model was built using the backward method. Table 3 illustrates the results obtained by univariate and multivariate analysis using the Fine and Gray Model. Probability of disease-specific event and death for patients with 0, 1, 2 risk was also calculated for the model. Statistical analysis was performed using R 12.2 (free statistical software by http://www.r-project.org, available at http://cran.r-project.org/ mirrors.html). 18 Salvage chemotherapy, HDC and stem cell mobilization ESHAP (etoposide, solumedrol, cisplatin and Ara-C) was primarily used as salvage chemotherapy and also for mobilization regimen for stem cell collection as we have reported previously. 19 BEAM was used as HDC.
Response evaluation and post-HDC auto-SCT evaluation
Patients on primary chemotherapy (CHOP in 47 (85%) had clinical and radiological response evaluation in the middle and at the end of planned initial treatment. After starting salvage chemotherapy, all patients had response evaluation after 2-3 cycles of ESHAP or rituximab þ ESHAP chemotherapy. Patients had restaging imaging evaluation after HDC auto-SCT at B100 days to check the disease status and also when clinically required.
Prognostic factors evaluation
Prognostic factor data were collected both at the time of diagnosis and before the initiation of salvage chemotherapy (after relapse, induction failure or progression) as described in the statistical section and shown in Table 1 and their significance in as shown Table 3 .
RESULTS
Patients' characteristics
Patients' characteristics before the initiation of salvage chemotherapy are shown in Table 1 . From January 2003 to September 2011, 85 consecutive patients with biopsy-proven aggressive lymphoma underwent HDC auto-SCT. Of these, 55 patients had FDG-PET after salvage chemotherapy/before HDC auto-SCT. Forty-five patients (82%) had DLBCL. Eight patients (15%) had anaplastic large cell lymphoma (T cell), one panniculitis-like T cell lymphoma and one peripheral T cell lymphoma not otherwise specified. Median age was 40 years at the time of HDC auto-SCT (14-63 years). Five patients were p21 years old and nineteen were 14-30 years. Only four patients were 460 years (60.35, 60.7, 61 and 62.7 years). In all, 19 out of 45 DLBCL patients had rituximab þ CHOP as first-line therapy.
Tissue confirmation at relapse or progression was obtained in 39 (71%) patients. This was 90% for relapsed patient as compared with 48% for refractory patients (P ¼ 0.001). Sixteen patients with no biopsy confirmation had unequivocal clinical/radiological evidence of relapse (three patients) or refractory/PD (thirteen patients). These 16 patients with no biopsy had stages II (4/16), III (5/16) and IV (7/16) before the initiation of salvage chemotherapy. Fourteen out of thirty-three patients who received rituximab þ ESHAP also had rituximab þ CHOP as first-line therapy. Diseasespecific EFS for DLBCL patients who received only CHOP and then rituximab þ ESHAP (20 patients) was 70% as compared with 64% (P ¼ 0.73) for those who had rituximab þ CHOP and then rituximab þ ESHAP (14 patients). Due to the small number of patients, further analysis is not performed. patients included in this analysis were enrolled in a prospective study evaluating FDG-PET before HDC auto-SCT. All these patients followed the same treatment guidelines and treatment was approved in the stem cell meeting.
FDG-PET reading All FDG-PET were reviewed by two experienced nuclear medicine experts (A Al-S and MA) as per uniformed guidelines. CT scan was reported as per institutional guidelines and scans were re-reviewed when needed by one body CT expert (Y Al-K).
Post-HDC auto-SCT evaluation and follow-up Post-HDC auto-SCT evaluation results are shown in Table 2 . Median follow-up of all alive patients from auto-SCT is 42.5 months (5-133 months). After HDC auto-SCT, 43 (78%) patients were in CR. Twenty-eight (50%) of these patients were already in CR as a result of ESHAP chemotherapy. PD was observed in 10 (18%) patients. At the time of current evaluation in June 2012 (Table 2) , 36 patients (66%) are still in CR. For the entire group, median disease-specific EFS and OS have not reached yet.
FDG-PET negative after salvage chemotherapy and outcome after HDC auto-SCT Thirty-three patients were FDG-PET negative after salvage chemotherapy. Of these 33 patients, 15 (45%) had negative CT Pre-transplant FDG-PET in aggressive lymphoma S Akhtar et al scan and 18 (55%) had positive CT scan. After HDC auto-SCT, 7 FDG-PET negative patients (21%) had a disease-specific event.
FDG-PET positive after salvage chemotherapy and outcome after HDC auto-SCT Twenty-two patients were FDG-PET positive after salvage chemotherapy. Of these, 21 (95%) also had positive CT scan. After HDC auto-SCT, 10 FDG-PET positive patients (45.5%) had a disease-specific event. The impacts of mediastinal involvement and FDG-PET positivity on disease-specific events and diseasespecific death with their P-values are provided in Figure 1 .
No patient received XRT between salvage chemotherapy and HDC auto-SCT. In all, 6 (27%) out of 22 FDG-PET positive patients as compared with 8 (24%) out of 33 FDG-PET negative (P ¼ 0.8) received XRT post-HDC auto-SCT.
Prognostic model development and outcome Statistical section provides the details of prognostic model development. Univariate analysis for disease-specific event included 19 factors, only 3 factors (B symptoms, mediastinal involvement and FDG-PET positive vs negative) showed a P-value of o0.2 and hence included into the multivariate model (Table 3) . FDG-PET was the only significant predictive factor for disease-specific event, HR ¼ 3.9(1.3-11.1), P-value ¼ 0.01.
Univariate analysis included the same group of risk factors for disease-specific death. FDG-PET positive vs negative and mediastinal involvement were the only significant factors, P-value was o0.2 and hence included into the multivariate analysis (Table 3) . Both remained significant (Figure 1) . Multivariate model revealed a significant P-value of 0.008. Models were developed using a 95% confidence level.
Each patient was then given a score of 0, 1 or 2 depending upon the number of these significant risk factors. Probability of disease-specific death at 5 year for patients with 0, 1, 2 risk factors was 5, 30 and 62%, respectively (P ¼ 0.01 and confidence interval 3-3.9%, 25.7-34.3% and 49.4-74.6%, respectively). This scorebased analysis indicates increasing risk of treatment failure for higher scores. Almost all studies have reported significantly inferior PFS in patients who have positive FDG-PET pre-transplant patients as compared with a negative FDG-PET. Schot et al. 12 reported 101 patients, 77 of whom underwent HDC auto-SCT and integrated FDG-PET with other prognostic factors. This study reported the impact of prognostic factors; second age adjusted international prognostic score and relapsed Hodgkin's prognostic score (rHPS) along with FDG-PET response. The patients were scored for three risk factors and outcome tabulated against FDG-PET CR, PR and no response. Although non-transplant patients were included in the analysis, the results revealed that patients with 2-3 risk factors and a positive pre-transplant FDG-PET had dismal prognoses.
Hoppe et al. 8 (83 DLBCL patients only) reported PFS of 48% for FDG-PET positive vs 77% for FDG-PET-negative patients (estimated from Kaplan-Meier graph as percentages are not reported). Multivariate analysis showed better PFS with negative FDG-PET, no extranodal disease and having involved field XRT as significant factors. Factors predicting a better OS were negative FDG-PET, no extranodal disease and TBI as conditioning, gender (P ¼ 0.051) and involved field XRT (P ¼ 0.059) in this study. We came across only two negative studies in auto-SCT setting, Stefani et al. 20 reported 60 patients and failed to show any significance of pre-transplant negative FDG-PET. This is still in the abstract form and details are not available. This study also included 17 Hodgkin's lymphoma in addition to 13 NHL patients transplanted in first complete remission. The reported OS was 78.1 vs 60.2% and PFS of 62.9 vs 60.4% for FDG-PET negative vs positive group, respectively. Roland et al. 5 used BEAM with and without Zevalin and failed to show any significance of negative FDG-PET (81 vs 88% P ¼ 11 for PFS and OS 88 vs 92% P ¼ 0.68). In most of the studies, a negative FDG-PET after salvage chemotherapy has been reported as a predictor for better PFS (66-96%) as compared with a positive FDG-PET scan (23-35% PFS) and in some studies, even for OS (77-100 vs 39-61%, respectively). 3, 4, 7, 9, 13, 15 Recently, there have been some reports of FDG-PET in reduced intensity or full allogeneic transplant. Four of these studies failed to show any impact of FDG-PET results [21] [22] [23] [24] while only one showed a negative effect of FDG-PET positivity in this setting. 25 As the treatment setting is completely different, we will not discuss this.
Our report supports previous studies reporting a negative impact of FDG-PET positivity before HDC auto-SCT both on disease-specific event and on mortality. Our data are from a large single institution PDG-PET pre-HDC auto-SCT data reporting the outcome of relapsed or refractory aggressive lymphoma. Our report includes a uniform data set including patients with aggressive lymphoma treated uniformly with ESHAP/R-ESHAP salvage and BEAM as HDC. Our study has some limitations like other studies: a large number of high risk/refractory patients due to referral bias and changing salvage from ESHAP to R-ESHAP. We analyzed a large number of prognostic factors in the setting of FDG-PET use including R-ESHAP vs ESHAP and age adjusted international prognostic index. Our results show the significance of this model (P ¼ 0.008). Prospective studies with an appropriate sample size to validating this model should be the next step. Our model, or any other, after validation, can be used for selecting potential high risk patients for clinical studies. With time, use of R-CHOP, R-Salvage, R-maintenance and other newer strategies will create multiple diversely treated groups of patients for similar conditions and this will make it difficult to find a uniform group in retrospective setting.
